Global Antiviral Drugs Treatment Market
Global Antiviral Drugs Treatment Market

Antiviral Drugs Treatment Comprehensive Study by Type (Reverse Transcriptase Inhibitors, Protease Inhibitors, Fusion Inhibitors, Immune System Modulators), Application (Hepatitis, HIV/AIDS, Herpes, Influenza) Players and Region - Global Market Outlook to 2026

Antiviral Drugs Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 210 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Antiviral Drugs Treatment Market?

Antiviral drugs are a type of medicine that has been used to treat viral infections such as measles, HIV, influenza, and hepatitis. Vaccines are widely used to prescribe such medicines. Furthermore, the majority of these medications are used to treat common viral infections, while only a few (full-spectrum antiviral drugs) are effective against a wide range of viruses. Antiviral drug demand is expected to increase as the incidence of viral infections such as HIV, hepatitis, respiratory syncytial virus (RSV), and influenza increases. Furthermore, the new COVID-19 situation has enhanced influenza virus surveillance among the general public. Along with checking for COVID-19 in the test sample offered by the symptomatic patient, numerous countries are now testing for influenza virus, which has improved the disease's diagnosis. WHO also encourages countries to maintain routine influenza surveillance and, where resources allow, test samples from influenza surveillance sites for influenza and SARS-CoV-2 viruses.

The market study is being classified by Type (Reverse Transcriptase Inhibitors, Protease Inhibitors, Fusion Inhibitors and Immune System Modulators), by Application (Hepatitis, HIV/AIDS, Herpes and Influenza) and major geographies with country level break-up.

AbbVie Inc. (United States), AstraZeneca(United Kingdom), Boehringer Ingelheim (Germany), Bristol-Meyrs Squibb Company (United States), Cipla Inc. (India), Gilead Sciences Inc. (United States), GlaxoSmithKline PLC (United Kingdom), Johnson & Johnson (United States), Novartis AG (Switzerland), Pfizer Inc. (United States) and Sanofi (France) are some of the key players profiled in the study.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Antiviral Drugs Treatment market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Antiviral Drugs Treatment market by Type, Application and Region.

On the basis of geography, the market of Antiviral Drugs Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Initiatives to Curb Viral Diseases by Public and Private Companies
  • Advancements in Epidemiology and Growing Awareness of Viral Diseases

Market Trend
  • Advancements in Molecular Biology Promoting Drug Development

Restraints
  • High Cost of Antiviral Drug Treatment

Opportunities
  • Rising Government Investment on Research and Development


In October 2020, Gilead Sciences, Inc. received the U.S. Food and Drug Administration (FDA) approval for its antiviral drug Veklury (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization.


Key Target Audience
Antiviral Drug Treatment Providers, Healthcare Industry, Pharmaceutical Industry, Regulatory Bodies and Governmental Bodies

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Fusion Inhibitors
  • Immune System Modulators
By Application
  • Hepatitis
  • HIV/AIDS
  • Herpes
  • Influenza
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Initiatives to Curb Viral Diseases by Public and Private Companies
      • 3.2.2. Advancements in Epidemiology and Growing Awareness of Viral Diseases
    • 3.3. Market Trends
      • 3.3.1. Advancements in Molecular Biology Promoting Drug Development
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antiviral Drugs Treatment, by Type, Application and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Antiviral Drugs Treatment (Value)
      • 5.2.1. Global Antiviral Drugs Treatment by: Type (Value)
        • 5.2.1.1. Reverse Transcriptase Inhibitors
        • 5.2.1.2. Protease Inhibitors
        • 5.2.1.3. Fusion Inhibitors
        • 5.2.1.4. Immune System Modulators
      • 5.2.2. Global Antiviral Drugs Treatment by: Application (Value)
        • 5.2.2.1. Hepatitis
        • 5.2.2.2. HIV/AIDS
        • 5.2.2.3. Herpes
        • 5.2.2.4. Influenza
      • 5.2.3. Global Antiviral Drugs Treatment Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Antiviral Drugs Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AbbVie Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca(United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Boehringer Ingelheim (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bristol-Meyrs Squibb Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cipla Inc. (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Gilead Sciences Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GlaxoSmithKline PLC (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Johnson & Johnson (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Sanofi (France)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Antiviral Drugs Treatment Sale, by Type, Application and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Antiviral Drugs Treatment (Value)
      • 7.2.1. Global Antiviral Drugs Treatment by: Type (Value)
        • 7.2.1.1. Reverse Transcriptase Inhibitors
        • 7.2.1.2. Protease Inhibitors
        • 7.2.1.3. Fusion Inhibitors
        • 7.2.1.4. Immune System Modulators
      • 7.2.2. Global Antiviral Drugs Treatment by: Application (Value)
        • 7.2.2.1. Hepatitis
        • 7.2.2.2. HIV/AIDS
        • 7.2.2.3. Herpes
        • 7.2.2.4. Influenza
      • 7.2.3. Global Antiviral Drugs Treatment Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antiviral Drugs Treatment: by Type(USD Million)
  • Table 2. Antiviral Drugs Treatment Reverse Transcriptase Inhibitors , by Region USD Million (2015-2020)
  • Table 3. Antiviral Drugs Treatment Protease Inhibitors , by Region USD Million (2015-2020)
  • Table 4. Antiviral Drugs Treatment Fusion Inhibitors , by Region USD Million (2015-2020)
  • Table 5. Antiviral Drugs Treatment Immune System Modulators , by Region USD Million (2015-2020)
  • Table 6. Antiviral Drugs Treatment: by Application(USD Million)
  • Table 7. Antiviral Drugs Treatment Hepatitis , by Region USD Million (2015-2020)
  • Table 8. Antiviral Drugs Treatment HIV/AIDS , by Region USD Million (2015-2020)
  • Table 9. Antiviral Drugs Treatment Herpes , by Region USD Million (2015-2020)
  • Table 10. Antiviral Drugs Treatment Influenza , by Region USD Million (2015-2020)
  • Table 11. South America Antiviral Drugs Treatment, by Country USD Million (2015-2020)
  • Table 12. South America Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 13. South America Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 14. Brazil Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 15. Brazil Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 16. Argentina Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 17. Argentina Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 18. Rest of South America Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 19. Rest of South America Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 20. Asia Pacific Antiviral Drugs Treatment, by Country USD Million (2015-2020)
  • Table 21. Asia Pacific Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 22. Asia Pacific Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 23. China Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 24. China Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 25. Japan Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 26. Japan Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 27. India Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 28. India Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 29. South Korea Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 30. South Korea Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 31. Taiwan Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 32. Taiwan Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 33. Australia Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 34. Australia Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 35. Rest of Asia-Pacific Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 36. Rest of Asia-Pacific Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 37. Europe Antiviral Drugs Treatment, by Country USD Million (2015-2020)
  • Table 38. Europe Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 39. Europe Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 40. Germany Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 41. Germany Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 42. France Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 43. France Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 44. Italy Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 45. Italy Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 46. United Kingdom Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 47. United Kingdom Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 48. Netherlands Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 49. Netherlands Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 50. Rest of Europe Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 51. Rest of Europe Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 52. MEA Antiviral Drugs Treatment, by Country USD Million (2015-2020)
  • Table 53. MEA Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 54. MEA Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 55. Middle East Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 56. Middle East Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 57. Africa Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 58. Africa Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 59. North America Antiviral Drugs Treatment, by Country USD Million (2015-2020)
  • Table 60. North America Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 61. North America Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 62. United States Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 63. United States Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 64. Canada Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 65. Canada Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 66. Mexico Antiviral Drugs Treatment, by Type USD Million (2015-2020)
  • Table 67. Mexico Antiviral Drugs Treatment, by Application USD Million (2015-2020)
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Antiviral Drugs Treatment: by Type(USD Million)
  • Table 80. Antiviral Drugs Treatment Reverse Transcriptase Inhibitors , by Region USD Million (2021-2026)
  • Table 81. Antiviral Drugs Treatment Protease Inhibitors , by Region USD Million (2021-2026)
  • Table 82. Antiviral Drugs Treatment Fusion Inhibitors , by Region USD Million (2021-2026)
  • Table 83. Antiviral Drugs Treatment Immune System Modulators , by Region USD Million (2021-2026)
  • Table 84. Antiviral Drugs Treatment: by Application(USD Million)
  • Table 85. Antiviral Drugs Treatment Hepatitis , by Region USD Million (2021-2026)
  • Table 86. Antiviral Drugs Treatment HIV/AIDS , by Region USD Million (2021-2026)
  • Table 87. Antiviral Drugs Treatment Herpes , by Region USD Million (2021-2026)
  • Table 88. Antiviral Drugs Treatment Influenza , by Region USD Million (2021-2026)
  • Table 89. South America Antiviral Drugs Treatment, by Country USD Million (2021-2026)
  • Table 90. South America Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 91. South America Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 92. Brazil Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 93. Brazil Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 94. Argentina Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 95. Argentina Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 96. Rest of South America Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 97. Rest of South America Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 98. Asia Pacific Antiviral Drugs Treatment, by Country USD Million (2021-2026)
  • Table 99. Asia Pacific Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 100. Asia Pacific Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 101. China Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 102. China Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 103. Japan Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 104. Japan Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 105. India Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 106. India Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 107. South Korea Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 108. South Korea Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 109. Taiwan Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 110. Taiwan Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 111. Australia Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 112. Australia Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 113. Rest of Asia-Pacific Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 114. Rest of Asia-Pacific Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 115. Europe Antiviral Drugs Treatment, by Country USD Million (2021-2026)
  • Table 116. Europe Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 117. Europe Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 118. Germany Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 119. Germany Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 120. France Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 121. France Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 122. Italy Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 123. Italy Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 124. United Kingdom Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 125. United Kingdom Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 126. Netherlands Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 127. Netherlands Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 128. Rest of Europe Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 129. Rest of Europe Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 130. MEA Antiviral Drugs Treatment, by Country USD Million (2021-2026)
  • Table 131. MEA Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 132. MEA Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 133. Middle East Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 134. Middle East Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 135. Africa Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 136. Africa Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 137. North America Antiviral Drugs Treatment, by Country USD Million (2021-2026)
  • Table 138. North America Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 139. North America Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 140. United States Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 141. United States Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 142. Canada Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 143. Canada Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 144. Mexico Antiviral Drugs Treatment, by Type USD Million (2021-2026)
  • Table 145. Mexico Antiviral Drugs Treatment, by Application USD Million (2021-2026)
  • Table 146. Research Programs/Design for This Report
  • Table 147. Key Data Information from Secondary Sources
  • Table 148. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antiviral Drugs Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Antiviral Drugs Treatment: by Application USD Million (2015-2020)
  • Figure 6. South America Antiviral Drugs Treatment Share (%), by Country
  • Figure 7. Asia Pacific Antiviral Drugs Treatment Share (%), by Country
  • Figure 8. Europe Antiviral Drugs Treatment Share (%), by Country
  • Figure 9. MEA Antiviral Drugs Treatment Share (%), by Country
  • Figure 10. North America Antiviral Drugs Treatment Share (%), by Country
  • Figure 11. Global Antiviral Drugs Treatment share by Players 2020 (%)
  • Figure 12. Global Antiviral Drugs Treatment share by Players (Top 3) 2020(%)
  • Figure 13. Global Antiviral Drugs Treatment share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 16. AbbVie Inc. (United States) Revenue: by Geography 2020
  • Figure 17. AstraZeneca(United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. AstraZeneca(United Kingdom) Revenue: by Geography 2020
  • Figure 19. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 20. Boehringer Ingelheim (Germany) Revenue: by Geography 2020
  • Figure 21. Bristol-Meyrs Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 22. Bristol-Meyrs Squibb Company (United States) Revenue: by Geography 2020
  • Figure 23. Cipla Inc. (India) Revenue, Net Income and Gross profit
  • Figure 24. Cipla Inc. (India) Revenue: by Geography 2020
  • Figure 25. Gilead Sciences Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Gilead Sciences Inc. (United States) Revenue: by Geography 2020
  • Figure 27. GlaxoSmithKline PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. GlaxoSmithKline PLC (United Kingdom) Revenue: by Geography 2020
  • Figure 29. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 30. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 31. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 33. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 35. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 36. Sanofi (France) Revenue: by Geography 2020
  • Figure 37. Global Antiviral Drugs Treatment: by Type USD Million (2021-2026)
  • Figure 38. Global Antiviral Drugs Treatment: by Application USD Million (2021-2026)
  • Figure 39. South America Antiviral Drugs Treatment Share (%), by Country
  • Figure 40. Asia Pacific Antiviral Drugs Treatment Share (%), by Country
  • Figure 41. Europe Antiviral Drugs Treatment Share (%), by Country
  • Figure 42. MEA Antiviral Drugs Treatment Share (%), by Country
  • Figure 43. North America Antiviral Drugs Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • AbbVie Inc. (United States)
  • AstraZeneca(United Kingdom)
  • Boehringer Ingelheim (Germany)
  • Bristol-Meyrs Squibb Company (United States)
  • Cipla Inc. (India)
  • Gilead Sciences Inc. (United States)
  • GlaxoSmithKline PLC (United Kingdom)
  • Johnson & Johnson (United States)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (United States)
  • Sanofi (France)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation